CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Sept. 20, 2021—MeMed announced FDA 510(k) clearance of the company’s MeMed BV test for use on the MeMed Key platform to help health care providers distinguish between bacterial and viral infections.
MeMed BV is an immune-based protein signature test that offers physicians a tool to help distinguish between bacterial and viral infections across multiple pathogens, even if the infection site is inaccessible or unknown. MeMed BV measures and computationally integrates the levels of three immune system proteins, TRAIL, IP-10, and CRP. The test provides a result within 15 minutes when run on the MeMed Key platform and has been cleared for children and adults.
Pages: 1 2